Insights

Innovative Technology Adoption CrystecPharma's proprietary mSAS® particle engineering technology positions it as a leader in the advanced development of bioavailable and stable pharmaceuticals, making it an attractive partner for companies seeking cutting-edge formulation solutions.

Sustainability Focus The company's recognition in sustainability awards indicates a commitment to environmentally responsible manufacturing, aligning with the increasing demand for sustainable practices in pharmaceutical production.

Market Presence & Recognition Active participation in major industry events like CPHI Frankfurt and multiple awards highlight CrystecPharma’s strong industry engagement and reputation, providing networking opportunities for potential collaborations or service expansions.

Growth Potential With revenues between 1M and 10M and recent industry awards, CrystecPharma exhibits growth momentum, presenting sales opportunities through expanded partnerships, technology licensing, or joint development projects.

Talent & Leadership Recognition of key personnel, such as the Women in Pharma Award to Development Director Lyn Daintree, suggests a strong leadership team that could be leveraged for high-level strategic alliances and collaborative R&D initiatives.

Similar companies to CrystecPharma

CrystecPharma Tech Stack

CrystecPharma uses 8 technology products and services including MySQL, Microsoft 365, Choices, and more. Explore CrystecPharma's tech stack below.

MySQL
Database
Microsoft 365
Email
Choices
Javascript Libraries
Modernizr
Javascript Libraries
Google Maps
Maps
Yoast SEO
Search Engines
Bootstrap
UI Frameworks
prettyPhoto
Web Tools And Plugins

Media & News

CrystecPharma's Email Address Formats

CrystecPharma uses at least 1 format(s):

CrystecPharma Email Formats	Example	Percentage
First.Last@crystecpharma.com	John.Doe@crystecpharma.com	74%
First@crystecpharma.com	John@crystecpharma.com	15%
FLast@crystecpharma.com	JDoe@crystecpharma.com	6%
First_Last@crystecpharma.com	John_Doe@crystecpharma.com	5%

Frequently Asked Questions

Where is CrystecPharma's headquarters located?

CrystecPharma's main headquarters is located at Norcroft Building, Richmond Road Bradford, BD7 1DP, GB. The company has employees across 2 continents, including EuropeAsia.

What is CrystecPharma's phone number?

You can contact CrystecPharma's main corporate office by phone at

+44-1274-23****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is CrystecPharma's official website and social media links?

CrystecPharma's official website is crystecpharma.com and has social profiles on LinkedIn.

What is CrystecPharma's NAICS code?

CrystecPharma's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does CrystecPharma have currently?

As of July 2025, CrystecPharma has approximately 20 employees across 2 continents, including EuropeAsia. Key team members include Chief Scientific Director: P. Y.Ceo: P. T.Co-Founder & Coo: Q. S.. Explore CrystecPharma's employee directory with LeadIQ.

What industry does CrystecPharma belong to?

CrystecPharma operates in the Pharmaceutical Manufacturing industry.

What technology does CrystecPharma use?

CrystecPharma's tech stack includes MySQLMicrosoft 365ChoicesModernizrGoogle MapsYoast SEOBootstrapprettyPhoto.

What is CrystecPharma's email format?

CrystecPharma's email format typically follows the pattern of First.Last@crystecpharma.com. Find more CrystecPharma email formats with LeadIQ.

CrystecPharma

Pharmaceutical ManufacturingUnited Kingdom11-50 Employees

Crystec Pharma is focused on applying supercritical fluid technology to improve the performance of medicines. We provide crystal and particle engineering solutions to the pharmaceutical industry, contributing to human health by enabling new and more effective therapies.

Applications of our mSAS® (modified Supercritical Anti-Solvent)  technology include enhancing the dissolution and bioavailability of drugs, optimising release profiles, as well as improving stability and processing characteristics. 

Our solutions include the following: 

                •	Crystal and particle engineering
                •	Stabilisation of therapeutic agents derived from biotechnology
                •	Polymorph screening
                •	Improved performance of poorly soluble drugs
                •	Improved bioavailabilty of small molecules
                •	Alternative routes of delivery such as inhaled therapy
                •	Taste masking
                •	Crystallisation seeds
                •	Residual solvent elimination